Searching. Please wait…
1583
37
170
29013
4402
2599
347
386
Abstract: Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disorders ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic steatosis may result from the dysfunction of multiple pathways and thus multiple molecular triggers involved in the disease have been described. The development of NASH entails the activation of inflammatory and fibrotic processes. Furthermore, NAFLD is also strongly associated with several extra-hepatic comorbidities, i.e., metabolic syndrome, type 2 diabetes mellitus, obesity, hypertension, cardiovascular disease and chronic kidney disease. Due to the heterogeneity of NAFLD presentations and the multifactorial etiology of the disease, clinical trials for NAFLD treatment are testing a wide range of interventions and drugs, with little success. Here, we propose a narrative review of the different phenotypic characteristics of NAFLD patients, whose disease may be triggered by different agents and driven along different pathophysiological pathways. Thus, correct phenotyping of NAFLD patients and personalized treatment is an innovative therapeutic approach that may lead to better therapeutic outcomes.
Fuente: International Journal of Molecular Sciences, 2023, 24(13), 10718
Publisher: MDPI
Year of publication: 2023
No. of pages: 28
Publication type: Article
DOI: 10.3390/ijms241310718
ISSN: 1661-6596,1422-0067
Publication Url: https://doi.org/10.3390/ijms241310718
Consult in UCrea Read publication
MARTA ALONSO PEÑA
BARRIO AZACETA, MARÍA DEL
PELETEIRO VIGIL, ANA
JIMÉNEZ GONZÁLEZ, CAROLINA
ALVARO SANTOS LASO
MARIA TERESA ARIAS LOSTE
PAULA IRUZUBIETA COZ
JAVIER CRESPO GARCIA
Back